Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)
  4. Volume 25, Issue 1
  5. Article
Volume 25, Issue 1
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Obesity and prediabetes affect a substantial part of the general population, but are largely underdiagnosed, underestimated, and undertreated. Prediabetes differs from diabetes only in the degree of hyperglycaemia consequent to the progressive decline in residual beta-cell function. Both prediabetes and diabetes occur as a consequence of insulin resistance that starts several years before the clinical onset of overt diabetes. Macrovascular complications in patients with diabetes are mainly caused by insulin resistance. This is why in prediabetes, the overall cardiovascular risk is, by all means, similar to that in patients with diabetes. It is important, therefore, to identify prediabetes and treat patients not only to prevent or delay the onset of diabetes, but to reduce the cardiovascular risk associated with prediabetes. This review provides an overview of the pathophysiology of prediabetes in patients with obesity and the progression toward overt diabetes. We have reviewed nutritional and pharmacological approaches to the management of obesity and reduced glucose tolerance, and the treatment of the major comorbidities in these patients, including hypertension, dyslipidaemia, and Metabolic dysfunction-associated Steatotic Liver Disease (MASLD), has also been reviewed. In patients with obesity and prediabetes, the nutritional approach is similar to that adopted for patients with obesity and diabetes; treatments of dyslipidaemia and hypertension also have the same targets compared to patients with diabetes. MASLD is a critical issue in these patients; in the prediabetic state, MASLD rarely progresses into fibrosis. This highlights the importance of the early recognition of this pathological condition before patients become diabetic when the risk of fibrosis is much higher. It is necessary to raise awareness of the clinical relevance of this pathological condition in order to prompt early intervention before complications occur. The single most important therapeutic goal is weight loss, which must be early and persistent.

© 2025 Bentham Science Publishers
© 2025 The Author(s). Published by Bentham Science Publisher. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303282327240507184902
2024-05-20
2025-01-17

  • From This Site

    /content/journals/emiddt/10.2174/0118715303282327240507184902
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/emiddt/25/1/EMIDDT-25-1-03.html?itemId=/content/journals/emiddt/10.2174/0118715303282327240507184902&mimeType=html&fmt=ahah

References

  1. Abarca-GómezL. AbdeenZ.A. HamidZ.A. Abu-RmeilehN.M. Acosta-CazaresB. AcuinC. AdamsR.J. AekplakornW. AfsanaK. Aguilar-SalinasC.A. AgyemangC. AhmadvandA. AhrensW. AjlouniK. AkhtaevaN. Al-HazzaaH.M. Al-OthmanA.R. Al-RaddadiR. Al BuhairanF. Al DhukairS. AliM.M. AliO. AlkerwiA. Alvarez-PedrerolM. AlyE. AmarapurkarD.N. AmouyelP. AmuzuA. AndersenL.B. AnderssenS.A. AndradeD.S. ÄngquistL.H. AnjanaR.M. Aounallah-SkhiriH. AraújoJ. AriansenI. ArisT. ArlappaN. ArveilerD. AryalK.K. AspelundT. AssahF.K. AssunçãoM.C.F. AungM.S. AvdicováM. AzevedoA. AziziF. BabuB.V. BahijriS. BakerJ.L. BalakrishnaN. BamoshmooshM. BanachM. BandoszP. BanegasJ.R. BarbagalloC.M. BarcelóA. BarkatA. BarrosA.J.D. BarrosM.V.G. BataI. BatiehaA.M. BatistaR.L. BatyrbekA. BaurL.A. BeagleholeR. RomdhaneH.B. BenedicsJ. BenetM. BennettJ.E. Bernabe-OrtizA. BernotieneG. BettiolH. BhagyalaxmiA. BharadwajS. BhargavaS.K. BhattiZ. BhuttaZ.A. BiH. BiY. BiehlA. BikbovM. BistaB. BjelicaD.J. BjerregaardP. BjertnessE. BjertnessM.B. BjörkelundC. BlokstraA. BoS. BobakM. BoddyL.M. BoehmB.O. BoeingH. BoggiaJ.G. BoissonnetC.P. BonaccioM. BongardV. BovetP. BraeckeveltL. BraeckmanL. BragtM.C.E. BrajkovichI. BrancaF. BreckenkampJ. BredaJ. BrennerH. BrewsterL.M. BrianG.R. BrinduseL. BrunoG. Bueno-de-MesquitaH.B. BuggeA. BuoncristianoM. BurazeriG. BurnsC. de LeónA.C. CacciottoloJ. CaiH. CamaT. CameronC. CamolasJ. CanG. CândidoA.P.C. CapanzanaM. CapuanoV. CardosoV.C. CarlssonA.C. CarvalhoM.J. CasanuevaF.F. CasasJ-P. CasertaC.A. ChamukuttanS. ChanA.W. ChanQ. ChaturvediH.K. ChaturvediN. ChenC-J. ChenF. ChenH. ChenS. ChenZ. ChengC-Y. ChetritA. Chikova-IscenerE. ChioleroA. ChiouS-T. Chirita-EmandiA. ChirlaqueM-D. ChoB. ChoY. ChristensenK. ChristofaroD.G. ChudekJ. CifkovaR. CintezaE. ClaessensF. ClaysE. ConcinH. ConfortinS.C. CooperC. CooperR. CoppingerT.C. CostanzoS. CottelD. CowellC. CraigC.L. CrujeirasA.B. CucuA. D’ArrigoG. d’OrsiE. DallongevilleJ. DamascenoA. DamsgaardC.T. DanaeiG. DanknerR. DantoftT.M. DastgiriS. DauchetL. DavletovK. De BackerG. De BacquerD. De CurtisA. de GaetanoG. De HenauwS. de OliveiraP.D. De RidderK. De SmedtD. DeepaM. DeevA.D. DehghanA. DelisleH. DelpeuchF. DeschampsV. DhanaK. Di CastelnuovoA.F. Dias-da-CostaJ.S. DiazA. DikaZ. DjalaliniaS. DoH.T.P. DobsonA.J. DonatiM.B. DonfrancescoC. DonosoS.P. DöringA. DorobantuM. DorostyA.R. DouaK. DrygasW. DuanJ.L. DuanteC. DulevaV. DulskieneV. DzerveV. Dziankowska-ZaborszczykE. EgbagbeE.E. EggertsenR. EibenG. EkelundU. El AtiJ. ElliottP. Engle-StoneR. ErasmusR.T. EremC. EriksenL. ErikssonJ.G. la PeñaJ.E. EvansA. FaehD. FallC.H. Sant’AngeloV.F. FarzadfarF. Felix-RedondoF.J. FergusonT.S. FernandesR.A. Fernández-BergésD. FerranteD. FerrariM. FerreccioC. FerrieresJ. FinnJ.D. FischerK. FloresE.M. FögerB. FooL.H. ForslundA-S. ForsnerM. FouadH.M. FrancisD.K. FrancoM.C. FrancoO.H. FronteraG. FuchsF.D. FuchsS.C. FujitaY. FurusawaT. GaciongZ. GafencuM. GaleoneD. GalvanoF. Garcia-de-la-HeraM. GaretaD. GarnettS.P. GaspozJ-M. GasullM. GatesL. GeigerH. GeleijnseJ.M. GhasemianA. GiampaoliS. GianfagnaF. GillT.K. GiovannelliJ. GiwercmanA. GodosJ. GogenS. GoldsmithR.A. GoltzmanD. GonçalvesH. González-LeonM. González-RivasJ.P. Gonzalez-GrossM. GottrandF. GraçaA.P. Graff-IversenS. GrafnetterD. GrajdaA. GrammatikopoulouM.G. GregorR.D. GrodzickiT. GrøntvedA. GrossoG. GrudenG. GrujicV. GuD. Gualdi-RussoE. Guallar-CastillónP. GuanO.P. GudmundssonE.F. GudnasonV. GuerreroR. GuessousI. GuimaraesA.L. GullifordM.C. GunnlaugsdottirJ. GunterM. GuoX. GuoY. GuptaP.C. GuptaR. GurejeO. GurzkowskaB. GutierrezL. GutzwillerF. HadaeghF. HadjigeorgiouC.A. Si-RamleeK. HalkjærJ. HambletonI.R. HardyR. KumarR.H. HassapidouM. HataJ. HayesA.J. HeJ. Heidinger-FelsoR. HeinenM. HendriksM.E. HenriquesA. CadenaL.H. HerralaS. HerreraV.M. Herter-AeberliI. HeshmatR. HihtaniemiI.T. HoS.Y. HoS.C. HobbsM. HofmanA. HopmanW.M. HorimotoA.R.V.R. HormigaC.M. HortaB.L. HoutiL. HowittC. HtayT.T. HtetA.S. HtikeM.M.T. HuY. HuertaJ.M. PetrescuC.H. HuismanM. HusseiniA. HuuC.N. HuybrechtsI. HwallaN. HyskaJ. IacovielloL. IannoneA.G. IbarluzeaJ.M. IbrahimM.M. IkedaN. IkramM.A. IrazolaV.E. IslamM. IsmailA-S. IvkovicV. IwasakiM. JacksonR.T. JacobsJ.M. JaddouH. JafarT. JamilK.M. JamrozikK. JanszkyI. JaraniJ. JasienskaG. JelakovicA. JelakovicB. JenningsG. JeongS-L. JiangC.Q. Jiménez-AcostaS.M. JoffresM. JohanssonM. JonasJ.B. JørgensenT. JoshiP. JovicD.P. JózwiakJ. JuoleviA. JurakG. JurešaV. KaaksR. KafatosA. KajantieE.O. Kalter-LeiboviciO. KamaruddinN.A. KapantaisE. KarkiK.B. KasaeianA. KatzJ. KauhanenJ. KaurP. KavousiM. KazakbaevaG. KeilU. BokerL.K. Keinänen-KiukaanniemiS. KelishadiR. KelleherC. KemperH.C.G. KengneA.P. KerimkulovaA. KerstingM. KeyT. KhaderY.S. KhaliliD. KhangY-H. KhateebM. KhawK-T. KhouwI.M.S.L. Kiechl-KohlendorferU. KiechlS. KillewoJ. KimJ. KimY-Y. KlimontJ. KlumbieneJ. KnoflachM. KoiralaB. KolleE. KolsterenP. KorrovitsP. KosJ. KoskinenS. KoudaK. KovacsV.A. KowlessurS. KozielS. KratzerW. KriemlerS. KristensenP.L. KrokstadS. KromhoutD. KrugerH.S. KubinovaR. KucieneR. KuhD. KujalaU.M. KulagaZ. KumarR.K. KunešováM. KurjataP. KusumaY.S. KuulasmaaK. KyobutungiC. LaQ.N. LaamiriF.Z. LaatikainenT. LachatC. LaidY. LamT.H. LandroveO. LanskaV. LappasG. LarijaniB. LaugsandL.E. LauriaL. LaxmaiahA. BaoK.L.N. LeT.D. LebananM.A.O. LeclercqC. LeeJ. LeeJ. LehtimäkiT. León-MuñozL.M. LevittN.S. LiY. LillyC.L. LimW-Y. Lima-CostaM.F. LinH-H. LinX. LindL. LinnebergA. LissnerL. LitwinM. LiuJ. LoitH-M. LopesL. LorbeerR. LotufoP.A. LozanoJ.E. LuksieneD. LundqvistA. LunetN. LytsyP. MaG. MaJ. Machado-CoelhoG.L.L. Machado-RodriguesA.M. MachiS. MaggiS. MaglianoD.J. MagriplisE. MahaletchumyA. MaireB. MajerM. MakdisseM. MalekzadehR. MalhotraR. RaoK.M. MalyutinaS. ManiosY. MannJ.I. ManzatoE. MargozziniP. MarkakiA. MarkeyO. MarquesL.P. Marques-VidalP. MarrugatJ. Martin-PrevelY. MartinR. MartorellR. MartosE. MarventanoS. MasoodiS.R. MathiesenE.B. MatijasevichA. MatshaT.E. MazurA. MbanyaJ.C.N. McFarlaneS.R. McGarveyS.T. McKeeM. McLachlanS. McLeanR.M. McLeanS.B. McNultyB.A. YusofS.M. Mediene-BenchekorS. MedzionieneJ. MeirhaegheA. MeisfjordJ. MeisingerC. MenezesA.M.B. MenonG.R. MensinkG.B.M. MeshramI.I. MetspaluA. MeyerH.E. MiJ. MichaelsenK.F. MichelsN. MikkelK. MillerJ.C. MindericoC.S. MiquelJ.F. MirandaJ.J. MirkopoulouD. MirrakhimovE. Mišigoj-DurakovicM. MistrettaA. MocanuV. ModestiP.A. MohamedM.K. MohammadK. MohammadifardN. MohanV. MohannaS. YusoffM.F.M. MolboD. MøllehaveL.T. MøllerN.C. MolnárD. MomenanA. MondoC.K. MonterrubioE.A. MonyekiK.D.K. MoonJ.S. MoreiraL.B. MorejonA. MorenoL.A. MorganK. MortensenE.L. MoschonisG. MossakowskaM. MostafaA. MotaJ. Mota-PintoA. MotlaghM.E. MottaJ. MuT.T. MucM. MuiesanM.L. Müller-NurasyidM. MurphyN. MursuJ. MurtaghE.M. MusilV. NabipourI. NagelG. NaiduB.M. NakamuraH. NámešnáJ. NangE.E.K. NangiaV.B. NankapM. NarakeS. NardoneP. Navarrete-MuñozE.M. NealW.A. NenkoI. NeoviusM. NerviF. NguyenC.T. NguyenN.D. NguyenQ.N. Nieto-MartínezR.E. NingG. NinomiyaT. NishtarS. NoaleM. NoboaO.A. NoratT. NorieS. NotoD. NsourM.A. O’ReillyD. ObrejaG. OdaE. OehlersG. OhK. OharaK. OlafssonÖ. OlintoM.T.A. OliveiraI.O. OltarzewskiM. OmarM.A. OnatA. OngS.K. OnoL.M. OrdunezP. OrnelasR. OrtizA.P. OslerM. OsmondC. OstojicS.M. OstovarA. OteroJ.A. OvervadK. Owusu-DaboE. PaccaudF.M. PadezC. PahomovaE. PajakA. PalliD. PalloniA. PalmieriL. PanW-H. Panda-JonasS. PandeyA. PanzaF. PapandreouD. ParkS-W. ParnellW.R. ParsaeianM. PascanuI.M. PatelN.D. PecinI. PednekarM.S. PeerN. PeetersP.H. PeixotoS.V. PeltonenM. PereiraA.C. Perez-FarinosN. PérezC.M. PetersA. PetkevicieneJ. PetrauskieneA. PeykariN. PhamS.T. PierannunzioD. PigeotI. PikhartH. PilavA. PilottoL. PistelliF. PitakakaF. PiwonskaA. Plans-RubióP. PohB.K. PohlabelnH. PopR.M. PopovicS.R. PortaM. PortegiesM.L.P. PoschG. PoulimeneasD. PouraramH. PourshamsA. PoustchiH. PradeepaR. PrashantM. PriceJ.F. PuderJ.J. PuduleI. PuiuM. PunabM. QasrawiR.F. QorbaniM. BaoT.Q. RadicI. RadisauskasR. RahmanM. RahmanM. RaitakariO. RajM. RaoS.R. RamachandranA. RamkeJ. RamosE. RamosR. RampalL. RampalS. Rascon-PachecoR.A. RedonJ. ReganitP.F.M. Ribas-BarbaL. RibeiroR. RiboliE. RigoF. de WitT.F.R. RitoA. Ritti-DiasR.M. RiveraJ.A. RobinsonS.M. RobitailleC. RodriguesD. Rodríguez-ArtalejoF. del Cristo Rodriguez-PerezM. Rodríguez-VillamizarL.A. Rojas-MartinezR. RojroongwasinkulN. RomagueraD. RonkainenK. RosengrenA. RouseI. RoyJ.G.R. RubinsteinA. RühliF.J. Ruiz-BetancourtB.S. RussoP. RutkowskiM. SabanayagamC. SachdevH.S. SaidiO. SalanaveB. MartinezE.S. SalmerónD. SalomaaV. SalonenJ.T. SalvettiM. Sánchez-AbantoJ. Sandjaja SansS. MarinaL.S. SantosD.A. SantosI.S. SantosO. dos SantosR.N. SantosR. SaramiesJ.L. SardinhaL.B. SarrafzadeganN. SaumK-U. SavvaS. SavyM. ScazufcaM. RosarioA.S. SchargrodskyH. SchienkiewitzA. SchipfS. SchmidtC.O. SchmidtI.M. SchultszC. SchutteA.E. SeinA.A. SenA. SenbanjoI.O. SepanlouS.G. Serra-MajemL. ShalnovaS.A. SharmaS.K. ShawJ.E. ShibuyaK. ShinD.W. ShinY. ShiriR. SianiA. SiantarR. SibaiA.M. SilvaA.M. SilvaD.A.S. SimonM. SimonsJ. SimonsL.A. SjöbergA. SjöströmM. SkovbjergS. Slowikowska-HilczerJ. SlusarczykP. SmeethL. SmithM.C. SnijderM.B. SoH-K. SobngwiE. SöderbergS. SoekatriM.Y.E. SolfrizziV. SonestedtE. SongY. SørensenT.I.A. SoricM. JéromeC.S. SoumareA. SpinelliA. SpiroskiI. StaessenJ.A. StammH. StarcG. StathopoulouM.G. StaubK. StavreskiB. Steene-JohannessenJ. StehleP. SteinA.D. StergiouG.S. StessmanJ. StieberJ. StöcklD. StocksT. StokwiszewskiJ. StrattonG. StronksK. StrufaldiM.W. Suárez-MedinaR. SunC-A. SundströmJ. SungY-T. SunyerJ. SuriyawongpaisalP. SwinburnB.A. SyR.G. SzponarL. TaiE.S. TammesooM-L. TamosiunasA. TanE.J. TangX. TanserF. TaoY. TarawnehM.R. TarpJ. Tarqui-MamaniC.B. TautuO-F. BraunerováR.T. TaylorA. TchibindatF. TheobaldH. TheodoridisX. ThijsL. ThuesenB.H. TjonnelandA. TolonenH.K. TolstrupJ.S. TopbasM. Topór-MadryR. TormoM.J. TornaritisM.J. TorrentM. ToselliS. TraissacP. TrichopoulosD. TrichopoulouA. TrinhO.T.H. TrivediA. TshepoL. TsiggaM. TsuganeS. Tulloch-ReidM.K. TulluF. TuomainenT-P. TuomilehtoJ. TurleyM.L. TyneliusP. TzotzasT. TzourioC. UedaP. UgelE.E. UkoliF.A.M. UlmerH. UnalB. UusitaloH.M.T. ValdiviaG. ValeS. ValviD. van der SchouwY.T. Van HerckK. Van MinhH. van RossemL. Van SchoorN.M. van ValkengoedI.G.M. VanderschuerenD. VanuzzoD. VattenL. VegaT. VeidebaumT. Velasquez-MelendezG. VelikaB. VeronesiG. VerschurenW.M.M. VictoraC.G. ViegiG. VietL. Viikari-JunturaE. VineisP. VioqueJ. VirtanenJ.K. Visvikis-SiestS. ViswanathanB. VlasoffT. VollenweiderP. VölzkeH. VoutilainenS. VrijheidM. WadeA.N. WagnerA. WaldhörT. WaltonJ. BebakarW.M.W. MohamudW.N.W. WanderleyR.S.Jr WangM-D. WangQ. WangY.X. WangY-W. WannametheeS.G. WarehamN. WeberA. WedderkoppN. WeerasekeraD. WhincupP.H. WidhalmK. WidyaheningI.S. WiecekA. WijgaA.H. WilksR.J. WilleitJ. WilleitP. WilsgaardT. WojtyniakB. Wong-McClureR.A. WongJ.Y.Y. WongJ.E. WongT.Y. WooJ. WoodwardM. WuF.C. WuJ. WuS. XuH. XuL. YamborisutU. YanW. YangX. YardimN. YeX. YiallourosP.K. YngveA. YoshiharaA. YouQ.S. Younger-ColemanN.O. YusoffF. YusoffM.F.M. ZaccagniL. ZafiropulosV. ZainuddinA.A. ZambonS. ZampelasA. ZamrazilováH. ZdrojewskiT. ZengY. ZhaoD. ZhaoW. ZhengW. ZhengY. ZholdinB. ZhouM. ZhuD. ZhussupovB. ZimmermannE. CisnerosJ.Z. BenthamJ. Di CesareM. BilanoV. BixbyH. ZhouB. StevensG.A. RileyL.M. TaddeiC. HajifathalianK. LuY. SavinS. CowanM.J. PaciorekC.J. Chirita-EmandiA. HayesA.J. KatzJ. KelishadiR. KengneA.P. KhangY-H. LaxmaiahA. LiY. MaJ. MirandaJ.J. MostafaA. NeoviusM. PadezC. RampalL. ZhuA. BennettJ.E. DanaeiG. BhuttaZ.A. EzzatiM. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: A pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults.Lancet2017390101132627264210.1016/S0140‑6736(17)32129‑329029897
     [Google Scholar]
  2. AndesL.J. ChengY.J. RolkaD.B. GreggE.W. ImperatoreG. Prevalence of prediabetes among adolescents and young adults in the United States, 2005-2016.JAMA Pediatr.20201742e19449810.1001/jamapediatrics.2019.449831790544
     [Google Scholar]
  3. ElSayedN.A. AleppoG. BannuruR.R. BruemmerD. CollinsB.S. EkhlaspourL. GagliaJ.L. HilliardM.E. JohnsonE.L. KhuntiK. LingvayI. MatfinG. McCoyR.G. PerryM.L. PillaS.J. PolskyS. PrahaladP. PratleyR.E. SegalA.R. SeleyJ.J. SelvinE. StantonR.C. GabbayR.A. 2. Diagnosis and classification of diabetes: Standards of care in diabetes—2024.Diabetes Care202447S1S20S4210.2337/dc24‑S00238078589
     [Google Scholar]
  4. HostalekU. Global epidemiology of prediabetes - Present and future perspectives.Clin. Diabetes Endocrinol.201951510.1186/s40842‑019‑0080‑031086677
     [Google Scholar]
  5. WangL. GaoP. ZhangM. HuangZ. ZhangD. DengQ. LiY. ZhaoZ. QinX. JinD. ZhouM. TangX. HuY. WangL. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013.JAMA2017317242515252310.1001/jama.2017.759628655017
     [Google Scholar]
  6. KarveA. HaywardR.A. Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic U.S. adults.Diabetes Care201033112355235910.2337/dc09‑195720724649
     [Google Scholar]
  7. CaiX. ZhangY. LiM. WuJ.H.Y. MaiL. LiJ. YangY. HuY. HuangY. Association between prediabetes and risk of all cause mortality and cardiovascular disease: Updated meta-analysis.BMJ2020370m229710.1136/bmj.m229732669282
     [Google Scholar]
  8. ElSayedN.A. AleppoG. BannuruR.R. BruemmerD. CollinsB.S. EkhlaspourL. GagliaJ.L. HilliardM.E. JohnsonE.L. KhuntiK. LingvayI. MatfinG. McCoyR.G. PerryM.L. PillaS.J. PolskyS. PrahaladP. PratleyR.E. SegalA.R. SeleyJ.J. SelvinE. StantonR.C. GabbayR.A. 3. Prevention or delay of diabetes and associated comorbidities: Standards of care in diabetes—2024.Diabetes Care202447S1S43S5110.2337/dc24‑S00338078581
     [Google Scholar]
  9. KnowlerW.C. Barrett-ConnorE. FowlerS.E. HammanR.F. LachinJ.M. WalkerE.A. NathanD.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.N. Engl. J. Med.2002346639340310.1056/NEJMoa01251211832527
     [Google Scholar]
  10. RooneyM.R. RawlingsA.M. PankowJ.S. Echouffo TcheuguiJ.B. CoreshJ. SharrettA.R. SelvinE. Risk of progression to diabetes among older adults with prediabetes.JAMA Intern. Med.2021181451151910.1001/jamainternmed.2020.877433555311
     [Google Scholar]
  11. LigthartS. van HerptT.T.W. LeeningM.J.G. KavousiM. HofmanA. StrickerB.H.C. van HoekM. SijbrandsE.J.G. FrancoO.H. DehghanA. Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: A prospective cohort study.Lancet Diabetes Endocrinol.201641445110.1016/S2213‑8587(15)00362‑926575606
     [Google Scholar]
  12. SouzaC.F. GrossJ.L. GerchmanF. LeitãoC.B. Prediabetes: Diagnosis, evaluation of chronic complications, and treatment.Arq. Bras. Endocrinol. Metabol201256527528410.1590/S0004‑2730201200050000122911279
     [Google Scholar]
  13. SchlesingerS. NeuenschwanderM. BarbareskoJ. LangA. MaalmiH. RathmannW. RodenM. HerderC. Prediabetes and risk of mortality, diabetes-related complications and comorbidities: Umbrella review of meta-analyses of prospective studies.Diabetologia202265227528510.1007/s00125‑021‑05592‑334718834
     [Google Scholar]
  14. FarrellC. MoranJ. Comparison of comorbidities in patients with pre-diabetes to those with diabetes mellitus type 2.Ir. Med. J.20141073727424757888
     [Google Scholar]
  15. American Diabetes Association Professional Practice Committee3. Prevention or delay of type 2 diabetes and associated comorbidities: Standards of Medical Care in Diabetes—2022.Diabetes Care202245S1S39S4534964876
     [Google Scholar]
  16. LingvayI. SumithranP. CohenR.V. le RouxC.W. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation.Lancet20223991032239440510.1016/S0140‑6736(21)01919‑X34600604
     [Google Scholar]
  17. StokesA. CollinsJ.M. GrantB.F. ScamuffaR.F. HsiaoC.W. JohnstonS.S. AmmannE.M. MansonJ.E. PrestonS.H. Obesity progression between young adulthood and midlife and incident diabetes: A retrospective cohort study of U.S. adults.Diabetes Care20184151025103110.2337/dc17‑233629506982
     [Google Scholar]
  18. MaloneJ.I. HansenB.C. Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite?Pediatr. Diabetes20192015910.1111/pedi.1278730311716
     [Google Scholar]
  19. BodenG. HomkoC. BarreroC.A. SteinT.P. ChenX. CheungP. FecchioC. KollerS. MeraliS. Excessive caloric intake acutely causes oxidative stress, GLUT4 carbonylation, and insulin resistance in healthy men.Sci. Transl. Med.20157304304re710.1126/scitranslmed.aac476526355033
     [Google Scholar]
  20. BorghiV.C. WajchenbergB.L. CesarF.P. Plasma glucagon suppressibility after oral glucose in obese subjects with normal and impaired glucose tolerance.Metabolism198433121068107410.1016/0026‑0495(84)90089‑16390086
     [Google Scholar]
  21. ThiebaudD. JacotE. DefronzoR.A. MaederE. JequierE. FelberJ.P. The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man.Diabetes1982311195796310.2337/diacare.31.11.9576757014
     [Google Scholar]
  22. SaltielA.R. OlefskyJ.M. Inflammatory mechanisms linking obesity and metabolic disease.J. Clin. Invest.201712711410.1172/JCI9203528045402
     [Google Scholar]
  23. CnopM. ToivonenS. EsteveI.M. SalpeaP. Endoplasmic reticulum stress and eIF2α phosphorylation: The Achilles heel of pancreatic β cells.Mol. Metab.2017691024103910.1016/j.molmet.2017.06.00128951826
     [Google Scholar]
  24. EfratS. Beta-Cell dedifferentiation in type 2 diabetes: Concise review.Stem Cells201937101267127210.1002/stem.305931298804
     [Google Scholar]
  25. ThomsenS.K. CeroniA. van de BuntM. BurrowsC. BarrettA. ScharfmannR. EbnerD. McCarthyM.I. GloynA.L. Systematic functional characterization of candidate causal genes for type 2 diabetes risk variants.Diabetes201665123805381110.2337/db16‑036127554474
     [Google Scholar]
  26. LinnemannA.K. BaanM. DavisD.B. Pancreatic β-cell proliferation in obesity.Adv. Nutr.20145327828810.3945/an.113.00548824829474
     [Google Scholar]
  27. CollinsF. Opening keynote: Omics data paves the way for more precise research into variances within diabetes.2023Available from: https://www.adameetingnews.org/live-updates/session-coverage/opening-keynote-omics-data-paves-the-way-for-more-precise-research-into-variances-within-diabetes/
  28. XueD. NarisuN. TaylorD.L. ZhangM. GrenkoC. TaylorH.J. YanT. TangX. SinhaN. ZhuJ. VandanaJ.J. Nok ChongA.C. LeeA. MansellE.C. SwiftA.J. ErdosM.R. ZhongA. BonnycastleL.L. ZhouT. ChenS. CollinsF.S. Functional interrogation of twenty type 2 diabetes-associated genes using isogenic human embryonic stem cell-derived β-like cells.Cell Metab.2023351118971914.e1110.1016/j.cmet.2023.09.01337858332
     [Google Scholar]
  29. Martín-PeláezS. FitoM. CastanerO. Mediterranean diet effects on type 2 diabetes prevention, disease progression, and related mechanisms. A review.Nutrients2020128223610.3390/nu1208223632726990
     [Google Scholar]
  30. VisserenF.L.J. MachF. SmuldersY.M. CarballoD. KoskinasK.C. BäckM. BenetosA. BiffiA. BoavidaJ.M. CapodannoD. CosynsB. CrawfordC. DavosC.H. DesormaisI. Di AngelantonioE. FrancoO.H. HalvorsenS. HobbsF.D.R. HollanderM. JankowskaE.A. MichalM. SaccoS. SattarN. TokgozogluL. TonstadS. TsioufisK.P. van DisI. van GelderI.C. WannerC. WilliamsB. De BackerG. ZagrosekR.V. AamodtA.H. AbdelhamidM. AboyansV. AlbusC. AsteggianoR. BäckM. BorgerM.A. BrotonsC. ČelutkienėJ. CifkovaR. CikesM. CosentinoF. DagresN. De BackerT. De BacquerD. DelgadoV. Den RuijterH. DendaleP. DrexelH. FalkV. FauchierL. FerenceB.A. FerrièresJ. FerriniM. FisherM. FliserD. FrasZ. GaitaD. GiampaoliS. GielenS. GrahamI. JenningsC. JorgensenT. Kautzky-WillerA. KavousiM. KoenigW. KonradiA. KotechaD. LandmesserU. LettinoM. LewisB.S. LinhartA. LøchenM-L. MakrilakisK. ManciaG. Marques-VidalP. McEvoyJ.W. McGreavyP. MerkelyB. NeubeckL. NielsenJ.C. PerkJ. PetersenS.E. PetronioA.S. PiepoliM. PogosovaN.G. PrescottE.I.B. RayK.K. ReinerZ. RichterD.J. RydénL. ShlyakhtoE. SitgesM. Sousa-UvaM. SudanoI. TiberiM. TouyzR.M. UngarA. VerschurenW.M.M. WiklundO. WoodD. ZamoranoJ.L. SmuldersY.M. CarballoD. KoskinasK.C. BäckM. BenetosA. BiffiA. BoavidaJ-M. CapodannoD. CosynsB. CrawfordC.A. DavosC.H. DesormaisI. AngelantonioD.E. DuranF.O.H. HalvorsenS. HobbsR.F.D. HollanderM. JankowskaE.A. MichalM. SaccoS. SattarN. TokgozogluL. TonstadS. TsioufisK.P. DisI. van GelderI.C. WannerC. WilliamsB. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice.Eur. Heart J.202142343227333710.1093/eurheartj/ehab48434458905
     [Google Scholar]
  31. GongQ. ZhangP. WangJ. MaJ. AnY. ChenY. ZhangB. FengX. LiH. ChenX. ChengY.J. GreggE.W. HuY. BennettP.H. LiG. QianX. ZhangL. HuiY. HeS. WangX. ThompsonT.J. GerzoffR.B. LiuP. JiangY. HuZ. WangJ. JiangX. ZhangJ. XiR. PangC. LiC. HuX. YangW. AnZ. SunX. ChenC. GangY. LiuJ. XiaoJ. CaoH. ZhengH. ZhangH. LiH. HongJ. LiuX. ZhaoF. WangW. ChenB. HowardB.V. EngelgauM.M. RoglicG. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the da qing diabetes prevention outcome study.Lancet Diabetes Endocrinol.20197645246110.1016/S2213‑8587(19)30093‑231036503
     [Google Scholar]
  32. TuomilehtoJ. LindströmJ. ErikssonJ.G. ValleT.T. HämäläinenH. ParikkaI.P. KiukaanniemiK.S. LaaksoM. LouherantaA. RastasM. SalminenV. AunolaS. CepaitisZ. MoltchanovV. HakumäkiM. MannelinM. MartikkalaV. SundvallJ. UusitupaM. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.N. Engl. J. Med.2001344181343135010.1056/NEJM20010503344180111333990
     [Google Scholar]
  33. RedmanL.M. HeilbronnL.K. MartinC.K. de JongeL. WilliamsonD.A. DelanyJ.P. RavussinE. Metabolic and behavioral compensations in response to caloric restriction: Implications for the maintenance of weight loss.PLoS One200942e437710.1371/journal.pone.000437719198647
     [Google Scholar]
  34. CarlssonA.C. ÄrnlövJ. SundströmJ. MichaëlssonK. BybergL. LindL. Physical activity, obesity and risk of cardiovascular disease in middle-aged men during a median of 30 years of follow-up.Eur. J. Prev. Cardiol.201623435936510.1177/204748731456803425604741
     [Google Scholar]
  35. ValenzuelaP.L. LozanoS.A. BarránA.T. NavarroF.P. GarcíaC.A. RuilopeL.M. InsuaR.D. OrdovasJ.M. LeyV. LuciaA. Joint association of physical activity and body mass index with cardiovascular risk: A nationwide population-based cross-sectional study.Eur. J. Prev. Cardiol.2022292e50e5210.1093/eurjpc/zwaa15133580798
     [Google Scholar]
  36. EvertA.B. DennisonM. GardnerC.D. GarveyW.T. LauK.H.K. MacLeodJ. MitriJ. PereiraR.F. RawlingsK. RobinsonS. SaslowL. UelmenS. UrbanskiP.B. YancyW.S.Jr Nutrition therapy for adults with diabetes or prediabetes: A consensus report.Diabetes Care201942573175410.2337/dci19‑001431000505
     [Google Scholar]
  37. The Diabetes Prevention Program Research GroupThe Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.Diabetes Care199922462363410.2337/diacare.22.4.62310189543
     [Google Scholar]
  38. Diabetes Prevention Program Research GroupLong-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: The Diabetes Prevention Program Outcomes Study.Lancet Diabetes Endocrinol.201531186687510.1016/S2213‑8587(15)00291‑026377054
     [Google Scholar]
  39. CerielloA. EspositoK. La SalaL. PujadasG. De NigrisV. TestaR. BucciarelliL. RondinelliM. GenoveseS. The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: A preliminary report.Cardiovasc Diabetol20141314010.1186/s12933‑014‑0140‑9
     [Google Scholar]
  40. IsmaelS. SilvestreM.P. VasquesM. AraújoJ.R. MoraisJ. DuarteM.I. PestanaD. FariaA. Pereira-LealJ.B. VazJ. RibeiroP. TeixeiraD. MarquesC. CalhauC. A pilot study on the metabolic impact of mediterranean diet in type 2 diabetes: Is gut microbiota the key?Nutrients2021134122810.3390/nu1304122833917736
     [Google Scholar]
  41. LiuY. WangY. NiY. CheungC.K.Y. LamK.S.L. WangY. XiaZ. YeD. GuoJ. TseM.A. PanagiotouG. XuA. Gut microbiome fermentation determines the efficacy of exercise for diabetes prevention.Cell Metab.20203117791.e510.1016/j.cmet.2019.11.00131786155
     [Google Scholar]
  42. Baena-DíezJ.M. PeñafielJ. SubiranaI. RamosR. ElosuaR. IbañezM.A. GuembeM.J. RigoF. DíazT.M.J. IribasM.C. CabréJ.J. SeguraA. LareoG.M. de la CámaraG.A. LapetraJ. QuesadaM. MarrugatJ. MedranoM.J. BerjónJ. FronteraG. GavrilaD. BarricarteA. BasoraJ. GarcíaJ.M. PavoneN.C. Lora-PablosD. MayoralE. FranchJ. MataM. CastellC. FrancesA. GrauM. Risk of cause-specific death in individuals with diabetes: A competing risks analysis.Diabetes Care201639111987199510.2337/dc16‑061427493134
     [Google Scholar]
  43. BalkE.M. EarleyA. RamanG. AvendanoE.A. PittasA.G. RemingtonP.L. Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: A systematic review for the Community Preventive Services Task Force.Ann. Intern. Med.2015163643745110.7326/M15‑045226167912
     [Google Scholar]
  44. WheelerM.L. DunbarS.A. JaacksL.M. KarmallyW. Mayer-DavisE.J. Wylie-RosettJ. YancyW.S.Jr Macronutrients, food groups, and eating patterns in the management of diabetes: A systematic review of the literature, 2010.Diabetes Care201235243444510.2337/dc11‑221622275443
     [Google Scholar]
  45. FranzM.J. MacLeodJ. EvertA. BrownC. GradwellE. HanduD. ReppertA. RobinsonM. Academy of nutrition and dietetics nutrition practice guideline for type 1 and type 2 diabetes in adults: Systematic review of evidence for medical nutrition therapy effectiveness and recommendations for integration into the nutrition care process.J. Acad. Nutr. Diet.2017117101659167910.1016/j.jand.2017.03.02228533169
     [Google Scholar]
  46. GrossJ.L. ZelmanovitzT. MoulinC.C. De MelloV. PerassoloM. LeitãoC. HoefelA. PaggiA. AzevedoM.J. Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: A randomized crossover trial.Diabetes Care200225464565110.2337/diacare.25.4.64511919119
     [Google Scholar]
  47. TrumboP. SchlickerS. YatesA.A. PoosM. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids.J. Am. Diet. Assoc.2002102111621163010.1016/S0002‑8223(02)90346‑912449285
     [Google Scholar]
  48. Salas-SalvadóJ. BullóM. EstruchR. RosE. CovasM.I. JuradoI.N. CorellaD. ArósF. GraciaG.E. GutiérrezR.V. RomagueraD. LapetraJ. RaventósL.R.M. MajemS.L. PintóX. BasoraJ. MuñozM.A. SorlíJ.V. GonzálezM.M.A. Prevention of diabetes with Mediterranean diets: A subgroup analysis of a randomized trial.Ann. Intern. Med.201416011-1010.7326/M13‑172524573661
     [Google Scholar]
  49. EspositoK. ChiodiniP. MaiorinoM.I. BellastellaG. PanagiotakosD. GiuglianoD. Which diet for prevention of type 2 diabetes? A meta-analysis of prospective studies.Endocrine201447110711610.1007/s12020‑014‑0264‑424744219
     [Google Scholar]
  50. ChiuT.H.T. PanW.H. LinM.N. LinC.L. Vegetarian diet, change in dietary patterns, and diabetes risk: A prospective study.Nutr. Diabetes2018811210.1038/s41387‑018‑0022‑429549240
     [Google Scholar]
  51. KahleovaH. PelikanovaT. Vegetarian diets in the prevention and treatment of type 2 diabetes.J. Am. Coll. Nutr.201534544845810.1080/07315724.2014.97689025915002
     [Google Scholar]
  52. SchwingshacklL. BogensbergerB. HoffmannG. Diet quality as assessed by the healthy eating index, alternate healthy eating index, dietary approaches to stop hypertension score, and health outcomes: An updated systematic review and meta-analysis of cohort studies.J. Acad. Nutr. Diet.2018118174100.e1110.1016/j.jand.2017.08.02429111090
     [Google Scholar]
  53. CauterV.E. KnutsonK.L. Sleep and the epidemic of obesity in children and adults.Eur. J. Endocrinol.2008159S1S59S6610.1530/EJE‑08‑029818719052
     [Google Scholar]
  54. Van CauterE. SpiegelK. TasaliE. LeproultR. Metabolic consequences of sleep and sleep loss.Sleep Med.200891S23S2810.1016/S1389‑9457(08)70013‑3
     [Google Scholar]
  55. AntzaC. KostopoulosG. MostafaS. NirantharakumarK. TahraniA. The links between sleep duration, obesity and type 2 diabetes mellitus.J. Endocrinol.2022252212514110.1530/JOE‑21‑015534779405
     [Google Scholar]
  56. IyeghaI.D. ChiehA.Y. BryantB.M. LiL. Associations between poor sleep and glucose intolerance in prediabetes.Psychoneuroendocrinology201911010444410.1016/j.psyneuen.2019.10444431546116
     [Google Scholar]
  57. RafalsonL. DonahueR.P. StrangesS. LamonteM.J. DmochowskiJ. DornJ. TrevisanM. Short sleep duration is associated with the development of impaired fasting glucose: The Western New York Health Study.Ann. Epidemiol.2010201288388910.1016/j.annepidem.2010.05.00220620078
     [Google Scholar]
  58. MostafaS.A. MenaS.C. AntzaC. BalanosG. NirantharakumarK. TahraniA.A. Sleep behaviours and associated habits and the progression of pre-diabetes to type 2 diabetes mellitus in adults: A systematic review and meta-analysis.Diab. Vasc. Dis. Res.202219311110.1177/1479164122108882435616501
     [Google Scholar]
  59. PanX.R. LiG.W. HuY.H. WangJ.X. YangW.Y. AnZ.X. HuZ.X. Juan-Lin XiaoJ.Z. CaoH.B. LiuP.A. JiangX.G. JiangY.Y. WangJ.P. ZhengH. ZhangH. BennettP.H. HowardB.V. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.Diabetes Care199720453754410.2337/diacare.20.4.5379096977
     [Google Scholar]
  60. KnowlerW.C. FowlerS.E. HammanR.F. ChristophiC.A. HoffmanH.J. BrennemanA.T. Brown-FridayJ.O. GoldbergR. VendittiE. NathanD.M. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study.Lancet200937497021677168610.1016/S0140‑6736(09)61457‑419878986
     [Google Scholar]
  61. LindströmJ. Ilanne-ParikkaP. PeltonenM. AunolaS. ErikssonJ.G. HemiöK. HämäläinenH. HärkönenP. KiukaanniemiK.S. LaaksoM. LouherantaA. MannelinM. PaturiM. SundvallJ. ValleT.T. UusitupaM. TuomilehtoJ. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: Follow-up of the finnish diabetes prevention study.Lancet200636895481673167910.1016/S0140‑6736(06)69701‑817098085
     [Google Scholar]
  62. HammanR.F. WingR.R. EdelsteinS.L. LachinJ.M. BrayG.A. DelahantyL. HoskinM. KriskaA.M. Mayer-DavisE.J. Pi-SunyerX. RegensteinerJ. VendittiB. RosettW.J. Effect of weight loss with lifestyle intervention on risk of diabetes.Diabetes Care20062992102210710.2337/dc06‑056016936160
     [Google Scholar]
  63. CastellanaM. ConteE. CignarelliA. PerriniS. GiustinaA. GiovanellaL. GiorginoF. TrimboliP. Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: A systematic review and meta-analysis.Rev. Endocr. Metab. Disord.202021151610.1007/s11154‑019‑09514‑y31705259
     [Google Scholar]
  64. BuenoN.B. de MeloI.S.V. de OliveiraS.L. da Rocha AtaideT. Very-low-carbohydrate ketogenic diet vs. low-fat diet for long-term weight loss: A meta-analysis of randomised controlled trials.Br. J. Nutr.201311071178118710.1017/S000711451300054823651522
     [Google Scholar]
  65. CasanuevaF.F. CastellanaM. BellidoD. TrimboliP. CastroA.I. SajouxI. CarneroR.G. ArbelaezG.D. CrujeirasA.B. OlmosM.M.A. Ketogenic diets as treatment of obesity and type 2 diabetes mellitus.Rev. Endocr. Metab. Disord.202021338139710.1007/s11154‑020‑09580‑732803691
     [Google Scholar]
  66. MorenoB. CrujeirasA.B. BellidoD. SajouxI. CasanuevaF.F. Obesity treatment by very low-calorie-ketogenic diet at two years: Reduction in visceral fat and on the burden of disease.Endocrine201654368169010.1007/s12020‑016‑1050‑227623967
     [Google Scholar]
  67. CaprioM. InfanteM. MoriconiE. ArmaniA. FabbriA. MantovaniG. MarianiS. LubranoC. PoggiogalleE. MigliaccioS. DoniniL.M. BascianiS. CignarelliA. ConteE. CeccariniG. BogazziF. CiminoL. CondorelliR.A. La VigneraS. CalogeroA.E. GambineriA. VignozziL. ProdamF. AimarettiG. LinsalataG. BuralliS. MonzaniF. AversaA. VettorR. SantiniF. VittiP. GnessiL. PagottoU. GiorginoF. ColaoA. LenziA. CaprioM. BogazziF. BeccutiG. BiondiB. CannavòS. ChiodiniI. De FeudisG. Di FrancescoS. Di GregorioA. FalloF. ForestaC. GiacchettiG. GranataR. IsidoriA.M. MagniP. MaiellaroP. CaprinoM.P. PivonelloR. PofiR. PontecorviA. SimeoliC. Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: Systematic review and consensus statement from the Italian Society of Endocrinology (SIE).J. Endocrinol. Invest.201942111365138610.1007/s40618‑019‑01061‑231111407
     [Google Scholar]
  68. Gomez-ArbelaezD. BellidoD. CastroA.I. Ordoñez-MayanL. CarreiraJ. GalbanC. Martinez-OlmosM.A. CrujeirasA.B. SajouxI. CasanuevaF.F. Body composition changes after very-low-calorie ketogenic diet in obesity evaluated by 3 standardized methods.J. Clin. Endocrinol. Metab.2017102248849810.1210/jc.2016‑238527754807
     [Google Scholar]
  69. KaulS. RothneyM.P. PetersD.M. WackerW.K. DavisC.E. ShapiroM.D. ErgunD.L. Dual-energy X-ray absorptiometry for quantification of visceral fat.Obesity20122061313131810.1038/oby.2011.39322282048
     [Google Scholar]
  70. MicklesfieldL.K. GoedeckeJ.H. PunyanityaM. WilsonK.E. KellyT.L. Dual-energy X-ray performs as well as clinical computed tomography for the measurement of visceral fat.Obesity20122051109111410.1038/oby.2011.36722240726
     [Google Scholar]
  71. GuY. YuH. LiY. MaX. LuJ. YuW. XiaoY. BaoY. JiaW. Beneficial effects of an 8-week, very low carbohydrate diet intervention on obese subjects.Evid. Based Complement. Alternat. Med.201320131810.1155/2013/76080423573151
     [Google Scholar]
  72. SvendsenP.F. JensenF.K. HolstJ.J. HaugaardS.B. NilasL. MadsbadS. The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women.Scand. J. Clin. Lab. Invest.201272541041910.3109/00365513.2012.69154222708619
     [Google Scholar]
  73. DemolS. Yackobovitch-GavanM. ShalitinS. NagelbergN. Gillon-KerenM. PhillipM. Low‐carbohydrate (low & high‐fat) versus high‐carbohydrate low‐fat diets in the treatment of obesity in adolescents.Acta Paediatr.200998234635110.1111/j.1651‑2227.2008.01051.x18826492
     [Google Scholar]
  74. PartsalakiI. KarvelaA. SpiliotisB.E. Metabolic impact of a ketogenic diet compared to a hypocaloric diet in obese children and adolescents.J. Pediatr. Endocrinol. Metab.2012257-869770410.1515/jpem‑2012‑013123155696
     [Google Scholar]
  75. GodayA. BellidoD. SajouxI. CrujeirasA.B. BurgueraB. García-LunaP.P. OleagaA. MorenoB. CasanuevaF.F. Short-term safety, tolerability and efficacy of a very low-calorie-ketogenic diet interventional weight loss program versus hypocaloric diet in patients with type 2 diabetes mellitus.Nutr. Diabetes201669e23010.1038/nutd.2016.3627643725
     [Google Scholar]
  76. SaslowL.R. DaubenmierJ.J. MoskowitzJ.T. KimS. MurphyE.J. PhinneyS.D. Ploutz-SnyderR. GoldmanV. CoxR.M. MasonA.E. MoranP. HechtF.M. Twelve-month outcomes of a randomized trial of a moderate-carbohydrate versus very low-carbohydrate diet in overweight adults with type 2 diabetes mellitus or prediabetes.Nutr. Diabetes201771230410.1038/s41387‑017‑0006‑929269731
     [Google Scholar]
  77. La VigneraS. CannarellaR. GalvanoF. GrilloA. AversaA. CiminoL. MagagniniC.M. MongioìL.M. CondorelliR.A. CalogeroA.E. The ketogenic diet corrects metabolic hypogonadism and preserves pancreatic ß-cell function in overweight/obese men: A single-arm uncontrolled study.Endocrine202172239239910.1007/s12020‑020‑02518‑833063272
     [Google Scholar]
  78. EnginA. The definition and prevalence of obesity and metabolic syndrome.Adv. Exp. Med. Biol.201796011710.1007/978‑3‑319‑48382‑5_128585193
     [Google Scholar]
  79. NijpelsG. Popp-SnijdersC. KostenseP.J. BouterL.M. HeineR.J. Fasting proinsulin and 2-h post-load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: The Hoorn Study.Diabetologia199639111311810.1007/BF004004218720611
     [Google Scholar]
  80. PfütznerA. PfütznerA.H. LarbigM. ForstT. Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus.Diabetes Technol. Ther.20046340541210.1089/15209150477419812415198846
     [Google Scholar]
  81. PfütznerA. KannP.H. PfütznerA.H. KuntT. LarbigM. WeberM.M. ForstT. Intact and total proinsulin: New aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance.Clin. Lab.2004509-1056757315481632
     [Google Scholar]
  82. ZetheliusB. BybergL. HalesC.N. LithellH. BerneC. Proinsulin and acute insulin response independently predict Type 2 diabetes mellitus in men—report from 27 years of follow-up study.Diabetologia2003461202610.1007/s00125‑002‑0995‑212637978
     [Google Scholar]
  83. BolinderJ. FernlundP. BorgH. ArnqvistH.J. BjörkE. BlohméG. ErikssonJ.W. NyströmL. ÖstmanJ. SundkvistG. Hyperproinsulinemia segregates young adult patients with newly diagnosed autoimmune (type 1) and non‐autoimmune (type 2) diabetes.Scand. J. Clin. Lab. Invest.200565758559410.1080/0036551050026186916271990
     [Google Scholar]
  84. VangipurapuJ. StančákováA. KuulasmaaT. KuusistoJ. LaaksoM. Both fasting and glucose-stimulated proinsulin levels predict hyperglycemia and incident type 2 diabetes: A population-based study of 9,396 Finnish men.PLoS One2015104e012402810.1371/journal.pone.012402825853252
     [Google Scholar]
  85. OhkuraT. InoueK. FujiokaY. NakanishiR. ShiochiH. SumiK. YamamotoN. MatsuzawaK. IzawaS. OhkuraH. KatoM. YamamotoK. TaniguchiS. The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: A small-scale clinical study.BMC Res. Notes20136145310.1186/1756‑0500‑6‑45324215809
     [Google Scholar]
  86. ChoiY.J. JeonS.M. ShinS. Impact of a ketogenic diet on metabolic parameters in patients with obesity or overweight and with or without type 2 diabetes: A meta-analysis of randomized controlled trials.Nutrients2020127200510.3390/nu1207200532640608
     [Google Scholar]
  87. KumarS. BehlT. SachdevaM. SehgalA. KumariS. KumarA. KaurG. YadavH.N. BungauS. Implicating the effect of ketogenic diet as a preventive measure to obesity and diabetes mellitus.Life Sci.202126411866110.1016/j.lfs.2020.11866133121986
     [Google Scholar]
  88. FatatiG. VLCD E VLCKD nel trattamento di obesi affetti da diabete non insulinodipendente o prediabete: Evidenze e riflessioni cliniche.Rec. Prog. Med.2020111949250232914777
     [Google Scholar]
  89. TorgersonJ.S. HauptmanJ. BoldrinM.N. SjöströmL. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.Diabetes Care200427115516110.2337/diacare.27.1.15514693982
     [Google Scholar]
  90. le RouxC.W. AstrupA. FujiokaK. GreenwayF. LauD.C.W. Van GaalL. OrtizR.V. WildingJ.P.H. SkjøthT.V. ManningL.S. Pi-SunyerX. HamannA. BarakatA. BlüherM. LinnT. MölleA. SegnerA. StüblerP. Tosch-SistingR. PaciniF. SantiniF. MarchesiniG. RotellaC.M. InvittiC. VettorR. BuscemiS. RayaP.M. FreijooF.C. de BarbaráR.G. CarraroR. BobilloE.R. de la CuestaC. FarsangC. CsaszarA. MarkiewiczZ.B. MusialikP.D. FranekE. OstrowskaL. GlinianowiczO.M. LalicN. MicicD. LudvikB. PaulweberB. PragerR. ScheenA. Van GaalL. AstrupA.V. HermansenK. MadsbadS. RissanenA. NieminenS. SavolainenM. KrempfM. RomonM. LavilleM. MarreM. MiraR. FinucaneF. VeenendaalA. van BerkumF. VidarsdóttirJ.S. Van de WalleV. MeestersE. HjelmesæthJ. KlemsdalT.O. KulsengB. Bach-KliegelB. LaederachK. VilligerL. GolayA. BilzS. SathyapalanT. BainS. KumarS. Le RouxC.W. LeanM.E.J. McGowanB. RehmanT. WildingJ. WittertG. CatersonI. ProiettoJ. PrinsJ. NetoB.G. GrossJ.L. ChacraA.R. HalpernA. de SuplicyA.H. ChowF.C.C. ThackerH.P. ChadhaM. ChandaliaH. UnnikrishnanA. KalraS. DeshpandeN. ShunmugaveluM. DeshmukhV.C. MaislosM. LiebermanG.S. ShimonI. SternN. NabriskiD. KarnieliE. ShehadehN. GalvezG.G. del GranellR.A.M. OrtizR.M.V. FrancoG.M. GurievaI. SuplotovaL.A. TroshinaE. RuyatkinaL.A. VoychikE.A. MartsevichS. StartsevaM.A. SeeberM.E. BadatA. EllisG. AltuntasY. GulerS. UlgenE. DelibasiT. ChettyT. HartR. JanzenJ. LabonteI. LauD. LiutkusJ. O’KeefeD. PadwalR. RansomT.P.P. TytusR. WeisnagelS.J. AdlerJ. AquaK. AronoffS.L. BedelG.W. BlevinsT.C. BlumenauJ. BrockmyreA.P. CallR.S. CanadasR. ChaykinL.B. CohenK. ConrowJ.K. DavisM.G. DowneyH.J. DrosmanS.R. DuckorS. FarmerH.F. FarrellJ. FehnelS. FinneranM.P. ForbesR. ForkerA. FredrickM. FujiokaK. GellerS.A. GillS. GlaserL. GrecoS.N. GreenwayF.L. HarperW. HermanL. HoekstraJ. IngebretsenR. IsonR. JainR.K. KaplanR. KasterS.R. HaaseG.A. KerznerB. KirsteinJ.L. KoltunW. KriegerD.R. LewisC.E. MadderR. MarpleR.N. McDermottE.J. MelloC.J. MillerA.B. MullenJ. NardandreaJ. O’NeilP. Pi-SunyerF.X. PucilloR.M. RheeC. RedrickS. PardiniA. RothmanJ. RubinoD.M. SellersG. SmithT. ByarsW.D. SouferJ. SussmanA.M. PatrickK. SchrammE.L. Van CleeffM. BergS.R. WyattH.R. SimonJ.A. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: A randomised, double-blind trial.Lancet2017389100771399140910.1016/S0140‑6736(17)30069‑728237263
     [Google Scholar]
  91. WildingJ.P.H. BatterhamR.L. CalannaS. DaviesM. Van GaalL.F. LingvayI. McGowanB.M. RosenstockJ. TranM.T.D. WaddenT.A. WhartonS. YokoteK. ZeuthenN. KushnerR.F. Once-weekly semaglutide in adults with overweight or obesity.N. Engl. J. Med.202138411989100210.1056/NEJMoa203218333567185
     [Google Scholar]
  92. HankoskyE.R. WangH. NeffL.M. KanH. WangF. AhmadN.N. StefanskiA. GarveyW.T. Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT ‐1 trial.Diabetes Obes. Metab.202325123748375610.1111/dom.1526937700443
     [Google Scholar]
  93. SjöströmL. Review of the key results from the Swedish Obese Subjects ( SOS ) trial – A prospective controlled intervention study of bariatric surgery.J. Intern. Med.2013273321923410.1111/joim.1201223163728
     [Google Scholar]
  94. JohnsonA.B. WebsterJ.M. SumC.F. HeseltineL. ArgyrakiM. CooperB.G. TaylorR. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.Metabolism19934291217122210.1016/0026‑0495(93)90284‑U8412779
     [Google Scholar]
  95. WrightA.D. CullC.A. MacleodK.M. HolmanR.R. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.J. Diabetes Complications200620639540110.1016/j.jdiacomp.2005.08.01017070446
     [Google Scholar]
  96. MadsenK.S. ChiY. MetzendorfM.I. RichterB. HemmingsenB. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.Cochrane Libr.2019201912CD00855810.1002/14651858.CD008558.pub231794067
     [Google Scholar]
  97. HermanW.H. HoergerT.J. BrandleM. HicksK. SorensenS. ZhangP. HammanR.F. AckermannR.T. EngelgauM.M. RatnerR.E. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.Ann. Intern. Med.2005142532333210.7326/0003‑4819‑142‑5‑200503010‑0000715738451
     [Google Scholar]
  98. ZinmanB. HarrisS.B. NeumanJ. GersteinH.C. RetnakaranR.R. RaboudJ. QiY. HanleyA.J.G. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): A double-blind randomised controlled study.Lancet2010376973510311110.1016/S0140‑6736(10)60746‑520605202
     [Google Scholar]
  99. RosenstockJ. KlaffL.J. SchwartzS. NorthrupJ. HolcombeJ.H. WilhelmK. TrautmannM. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes.Diabetes Care20103361173117510.2337/dc09‑120320332357
     [Google Scholar]
  100. FríasJ.P. DaviesM.J. RosenstockJ. ManghiP.F.C. LandóL. BergmanB.K. LiuB. CuiX. BrownK. SURPASS-2 Investigators. Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes.N. Engl. J. Med.2021385650351510.1056/NEJMoa210751934170647
     [Google Scholar]
  101. MonamiM. NardiniC. MannucciE. Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: A meta‐analysis of randomized clinical trials.Diabetes Obes. Metab.201416545746610.1111/dom.1224424320621
     [Google Scholar]
  102. LundkvistP. PereiraM.J. KatsogiannosP. SjöströmC.D. JohnssonE. ErikssonJ.W. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.Diabetes Obes. Metab.20171991276128810.1111/dom.1295428345814
     [Google Scholar]
  103. McMurrayJ.J.V. SolomonS.D. InzucchiS.E. KøberL. KosiborodM.N. MartinezF.A. PonikowskiP. SabatineM.S. AnandI.S. BělohlávekJ. BöhmM. ChiangC.E. ChopraV.K. de BoerR.A. DesaiA.S. DiezM. DrozdzJ. DukátA. GeJ. HowlettJ.G. KatovaT. KitakazeM. LjungmanC.E.A. MerkelyB. NicolauJ.C. O’MearaE. PetrieM.C. VinhP.N. SchouM. TereshchenkoS. VermaS. HeldC. DeMetsD.L. DochertyK.F. JhundP.S. BengtssonO. SjöstrandM. LangkildeA.M. Dapagliflozin in patients with heart failure and reduced ejection fraction.N. Engl. J. Med.2019381211995200810.1056/NEJMoa191130331535829
     [Google Scholar]
  104. InzucchiS.E. DochertyK.F. KøberL. KosiborodM.N. MartinezF.A. PonikowskiP. SabatineM.S. SolomonS.D. VermaS. BělohlávekJ. BöhmM. ChiangC.E. de BoerR.A. DiezM. DukátA. LjungmanC.E.A. BengtssonO. LangkildeA.M. SjöstrandM. JhundP.S. McMurrayJ.J.V. Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: An exploratory analysis from DAPA-HF.Diabetes Care202144258659410.2337/dc20‑167533355302
     [Google Scholar]
  105. AnkerS.D. ButlerJ. FilippatosG. FerreiraJ.P. BocchiE. BöhmM. RoccaB.L.H.P. ChoiD.J. ChopraV. ValenzuelaC.E. GiannettiN. MesaG.J.E. JanssensS. JanuzziJ.L. JuanateyG.J.R. MerkelyB. NichollsS.J. PerroneS.V. PiñaI.L. PonikowskiP. SenniM. SimD. SpinarJ. SquireI. TaddeiS. TsutsuiH. VermaS. VinereanuD. ZhangJ. CarsonP. LamC.S.P. MarxN. ZellerC. SattarN. JamalW. SchnaidtS. SchneeJ.M. BrueckmannM. PocockS.J. ZannadF. PackerM. Empagliflozin in heart failure with a preserved ejection fraction.N. Engl. J. Med.2021385161451146110.1056/NEJMoa210703834449189
     [Google Scholar]
  106. RossingP. InzucchiS.E. VartP. JongsN. DochertyK.F. JhundP.S. KøberL. KosiborodM.N. MartinezF.A. PonikowskiP. SabatineM.S. SolomonS.D. DeMetsD.L. BengtssonO. LindbergM. LangkildeA.M. SjöstrandM. StefanssonB.V. KarlssonC. ChertowG.M. HouF.F. Correa-RotterR. TotoR.D. WheelerD.C. McMurrayJ.J.V. HeerspinkH.J.L. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: Pooled analysis of the DAPA-CKD and DAPA-HF trials.Lancet Diabetes Endocrinol.2022101243410.1016/S2213‑8587(21)00295‑334856173
     [Google Scholar]
  107. HeerspinkH.J.L. StefánssonB.V. Correa-RotterR. ChertowG.M. GreeneT. HouF.F. MannJ.F.E. McMurrayJ.J.V. LindbergM. RossingP. SjöströmC.D. TotoR.D. LangkildeA.M. WheelerD.C. Dapagliflozin in patients with chronic kidney disease.N. Engl. J. Med.2020383151436144610.1056/NEJMoa202481632970396
     [Google Scholar]
  108. ChilcottJ. TappendenP. JonesM.L. WightJ.P. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.Clin. Ther.200123111792182310.1016/S0149‑2918(00)80078‑811768834
     [Google Scholar]
  109. DeFronzoR.A. BanerjiM. BrayG.A. BuchananT.A. ClementS. HenryR.R. KitabchiA.E. MudaliarS. MusiN. RatnerR. ReavenP.D. SchwenkeD. StentzF.B. TripathyD. Actos Now for the prevention of diabetes (ACT NOW) study.BMC Endocr. Disord.2009911710.1186/1472‑6823‑9‑1719640291
     [Google Scholar]
  110. DeFronzoR.A. TripathyD. SchwenkeD.C. BanerjiM. BrayG.A. BuchananT.A. ClementS.C. GastaldelliA. HenryR.R. KitabchiA.E. MudaliarS. RatnerR.E. StentzF.B. MusiN. ReavenP.D. Prevention of diabetes with pioglitazone in ACT NOW: Physiologic correlates.Diabetes201362113920392610.2337/db13‑026523863810
     [Google Scholar]
  111. TripathyD. SchwenkeD.C. BanerjiM. BrayG.A. BuchananT.A. ClementS.C. HenryR.R. KitabchiA.E. MudaliarS. RatnerR.E. StentzF.B. MusiN. ReavenP.D. DeFronzoR.A. Diabetes incidence and glucose tolerance after termination of pioglitazone therapy: Results from ACT NOW.J. Clin. Endocrinol. Metab.201610152056206210.1210/jc.2015‑420226982008
     [Google Scholar]
  112. ChiassonJ.L. JosseR.G. GomisR. HanefeldM. KarasikA. LaaksoM. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial.Lancet200235993232072207710.1016/S0140‑6736(02)08905‑512086760
     [Google Scholar]
  113. HolmanR.R. ColemanR.L. ChanJ.C.N. ChiassonJ.L. FengH. GeJ. GersteinH.C. GrayR. HuoY. LangZ. McMurrayJ.J. RydénL. SchröderS. SunY. TheodorakisM.J. TenderaM. TuckerL. TuomilehtoJ. WeiY. YangW. WangD. HuD. PanC. KeenanJ. MiltonJ. DoranZ. BrayC. RouleauJ.L. CollierJ. PocockS. StandlE. SwedbergK. WengJ. ZhaoD. PetrieM.C. ConnollyE. JhundP. MacDonaldM. MylesR.C. BaiR. LiJ. LiuZ. LiuZ. PengD. TongQ. WangC. YanX. ZhangY. ZhouJ. SattarN. FisherM. PetrieJ.R. BethelM.A. XuW. HearnS. KappaiA. SuS-Y. LiyanageW. PaulS. PozziE. RingA. AthwalR. BatraP. FerchA. GrovesN. KennedyI. NawalaniecO. PatelY. RobertsR. RushV. StarrettJ. TangJ. BiJ. JiangZ. WeiH. WeiX. ZhangX. YinJ. SunY. HuR. LiuY. LongJ. LongY. QiaoG. QiaoH. SunX. ZhangY. ZhouJ. WangB. ChenB. DengL. HanX. HuT. HuaQ. HuoY. LiH. LiH. LiuL. LuJ. MaC. PengJ. PiL. WangB. WeiG. YangM. ZhangS. ZhangL. ZhaoX. ZhouY. ShiL. WangM. WuL. HanL. LiaoR. RanB. SheQ. TanJ. XiaM. YangC. ChenL. XiongS. YuL. PuX. WangY. XieQ. ChenC. ChenJ. DongY. WuZ. YuanY. ZhouW. ZhouS. ChenX. WuC. ZhangA. LiZ. LaiS. YangJ. WeiJ. KuangR. ZhaoZ. ZhongG. CaoX. HaoY. LiuG. WangD. FangH. KongL. LiH. WangC. WangL. LiX. DongP. ZhangS. LiuX. ZhaoY. LiuH. GuY. LiaoY. SuX. WangD. WangH. YangB. GuoY. OuyangD. YangT. ZhangY. HanY. LinX. ZhaoR. ManR. BianR. BiaoX. HasimuB. JinH. LiuP. YuJ. ZhangH. XuC. GuoY. LvK. TaoY. XuX. YangZ. LiD. QiC. ZhangG. GuX. HongL. HuL. LiJ. YangP. LiuB. WangG. LinH. LiuJ. ZhangS. HanP. JinY. LiL. LiZ. LuanH. SongM. XueL. HuaY. LiuD. YuanZ. YeJ. GaoF. FengJ. WangA. YeS. LiX. SuG. ZhangS. HouZ. JiangW. ZhouC. WangY. QiW. BaoX. FengB. GongH. GuS. GuM. GuoX. HeB. HuangY. JiangJ. JiangY. JinH. LiY. LiuQ. LuG. MiaoP. QinY. WangB. WangY. WuS. XuY. MaJ. ChenX. LiuX. TangJ. WangJ. ChenX. TaoJ. ZhangJ. ZhangT. LiD. DuX. JiangT. LinJ. LuC. MaH. GaoB. GuoX. LiT. ZhengS. LiZ. ZhaoS. QiuQ. LiK. LiuJ. TangB. YuanZ. ZhouJ. BaiW. GuoT. ZhangG. ZhangH. HaoY. FuG. TangL. ChenJ. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): A randomised, double-blind, placebo-controlled trial.Lancet Diabetes Endocrinol.201751187788610.1016/S2213‑8587(17)30309‑128917545
     [Google Scholar]
  114. ColemanR.L. ScottC.A.B. LangZ. BethelM.A. TuomilehtoJ. HolmanR.R. Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes.Cardiovasc. Diabetol.201918113510.1186/s12933‑019‑0933‑y31623625
     [Google Scholar]
  115. GarberA.J. HandelsmanY. GrunbergerG. EinhornD. AbrahamsonM.J. BarzilayJ.I. BlondeL. BushM.A. DeFronzoR.A. GarberJ.R. GarveyW.T. HirschI.B. JellingerP.S. McGillJ.B. MechanickJ.I. PerreaultL. RosenblitP.D. SamsonS. UmpierrezG.E. Consensus statement by the American Association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm -2020 executive summary.Endocr. Pract.202026110713910.4158/CS‑2019‑047232022600
     [Google Scholar]
  116. CatenaC. ColussiG. MartinisF. PezzuttoF. SechiL.A. Plasma glucose levels and left ventricular diastolic function in nondiabetic hypertensive patients.Am. J. Hypertens.201326111353136110.1093/ajh/hpt11423846724
     [Google Scholar]
  117. EmdinC.A. AndersonS.G. WoodwardM. RahimiK. Usual blood pressure and risk of new-onset diabetes: Evidence from 4.1 million adults and a meta-analysis of prospective studies.J. Am. Coll. Cardiol.201566141552156210.1016/j.jacc.2015.07.05926429079
     [Google Scholar]
  118. QiuM. ShenW. SongX. JuL. TongW. WangH. ZhengS. JinY. WuY. WangW. TianJ. Effects of prediabetes mellitus alone or plus hypertension on subsequent occurrence of cardiovascular disease and diabetes mellitus: Longitudinal study.Hypertension201565352553010.1161/HYPERTENSIONAHA.114.0463225624343
     [Google Scholar]
  119. BangaloreS. KumarS. LobachI. MesserliF.H. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: Observations from traditional and bayesian random-effects meta-analyses of randomized trials.Circulation20111232427992810, 9, 81010.1161/CIRCULATIONAHA.110.01633721632497
     [Google Scholar]
  120. CosentinoF. GrantP.J. AboyansV. BaileyC.J. CerielloA. DelgadoV. FedericiM. FilippatosG. GrobbeeD.E. HansenT.B. HuikuriH.V. JohanssonI. JüniP. LettinoM. MarxN. MellbinL.G. ÖstgrenC.J. RoccaB. RoffiM. SattarN. SeferovićP.M. Sousa-UvaM. ValensiP. WheelerD.C. PiepoliM.F. BirkelandK.I. AdamopoulosS. AjjanR. AvogaroA. BaigentC. BrodmannM. BuenoH. CeconiC. ChioncelO. CoatsA. ColletJ-P. CollinsP. CosynsB. Di MarioC. FisherM. FitzsimonsD. HalvorsenS. HansenD. HoesA. HoltR.I.G. HomeP. KatusH.A. KhuntiK. KomajdaM. LambrinouE. LandmesserU. LewisB.S. LindeC. LorussoR. MachF. MuellerC. NeumannF-J. PerssonF. PetersenS.E. PetronioA.S. RichterD.J. RosanoG.M.C. RossingP. RydénL. ShlyakhtoE. SimpsonI.A. TouyzR.M. WijnsW. WilhelmM. WilliamsB. AboyansV. BaileyC.J. CerielloA. DelgadoV. FedericiM. FilippatosG. GrobbeeD.E. HansenT.B. HuikuriH.V. JohanssonI. JüniP. LettinoM. MarxN. MellbinL.G. ÖstgrenC.J. RoccaB. RoffiM. SattarN. SeferovićP.M. Sousa-UvaM. ValensiP. WheelerD.C. WindeckerS. AboyansV. BaigentC. ColletJ-P. DeanV. DelgadoV. FitzsimonsD. GaleC.P. GrobbeeD.E. HalvorsenS. HindricksG. IungB. JüniP. KatusH.A. LandmesserU. LeclercqC. LettinoM. LewisB.S. MerkelyB. MuellerC. PetersenS.E. PetronioA.S. RichterD.J. RoffiM. ShlyakhtoE. SimpsonI.A. Sousa-UvaM. TouyzR.M. ZelveianP.H. ScherrD. JahangirovT. LazarevaI. ShivalkarB. NaserN. GruevI. MilicicD. PetrouP.M. LinhartA. HildebrandtP. Hasan-AliH. MarandiT. LehtoS. MansouratiJ. KurashviliR. SiasosG. LengyelC. ThrainsdottirI.S. AronsonD. Di LenardaA. RaissovaA. IbrahimiP. AbilovaS. TrusinskisK. SaadeG. BenlaminH. PetrulionieneZ. BanuC. MagriC.J. DavidL. BoskovicA. AlamiM. LiemA.H. BosevskiM. SvingenG.F.T. JanionM. GavinaC. VinereanuD. NedogodaS. ManciniT. IlicM.D. FabryovaL. FrasZ. NavarroJ.M.F. NorhammarA. LehmannR. MouraliM.S. UralD. NesukayE. ChowdhuryT.A. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.Eur. Heart J.202041225532310.1093/eurheartj/ehz48631497854
     [Google Scholar]
  121. ZidekW. SchraderJ. LüdersS. MatthaeiS. HasslacherC. HoyerJ. ZemmrichC. BramlageP. SturmC.D. PaarW.D. Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study.Cardiovasc. Diabetol.2012111110.1186/1475‑2840‑11‑122230104
     [Google Scholar]
  122. NazarzadehM. BidelZ. CanoyD. CoplandE. WamilM. MajertJ. Smith ByrneK. SundströmJ. TeoK. DavisB.R. ChalmersJ. PepineC.J. DehghanA. BennettD.A. SmithG.D. RahimiK. Blood pressure lowering and risk of new-onset type 2 diabetes: An individual participant data meta-analysis.Lancet2021398103131803181010.1016/S0140‑6736(21)01920‑634774144
     [Google Scholar]
  123. FeingoldK.R. Obesity and Dyslipidemia, 2000. MDText.com, Inc., South Dartmouth (MA),Available from: https://europepmc.org/article/NBK/nbk305895
  124. GrundyS.M. AraiH. BarterP. BersotT.P. BetteridgeD.J. CarmenaR. CuevasA. DavidsonM.H. GenestJ. KesäniemiY.A. SadikotS. SantosR.D. SusekovA. SyR. TokgozogluL. WattsG.F. ZhaoD. An international atherosclerosis society position paper: Global recommendations for the management of dyslipidemia: Executive summary.Atherosclerosis2014232241041310.1016/j.atherosclerosis.2013.11.03124468156
     [Google Scholar]
  125. GrundyS.M. StoneN.J. BaileyA.L. BeamC. BirtcherK.K. BlumenthalR.S. BraunL.T. de FerrantiS. TommasinoF.J. FormanD.E. GoldbergR. HeidenreichP.A. HlatkyM.A. JonesD.W. JonesL.D. PajaresL.N. NdumeleC.E. OrringerC.E. PeraltaC.A. SaseenJ.J. SmithS.C.Jr SperlingL. ViraniS.S. YeboahJ. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American college of cardiology/American heart association task force on clinical practice guidelines.Circulation201913925e1082e114330586774
     [Google Scholar]
  126. JellingerP.S. HandelsmanY. RosenblitP.D. BloomgardenZ.T. FonsecaV.A. GarberA.J. GrunbergerG. GuerinC.K. BellD.S.H. MechanickJ.I. Pessah-PollackR. WyneK. SmithD. BrintonE.A. FazioS. DavidsonM. JellingerP.S. HandelsmanY. BellD.S.H. BloomgardenZ.T. BrintonE.A. DavidsonM.H. FazioS. FonsecaV.A. GarberA.J. GrunbergerG. GuerinC.K. MechanickJ.I. Pessah-PollackR. RosenblitP.D. SmithD.A. WyneK. BushM. ZangenehF. HandelsmanY. BellD.S.H. BloomgardenZ.T. BrintonE.A. FazioS. FonsecaV.A. GarberA.J. GrunbergerG. GuerinC.K. JellingerP.S. RosenblitP.D. SmithD.A. WyneK. DavidsonM.H. American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease.Endocr. Pract.201723S118710.4158/EP171764.APPGL28437620
     [Google Scholar]
  127. MachF. BaigentC. CatapanoA.L. KoskinasK.C. CasulaM. BadimonL. ChapmanM.J. De BackerG.G. DelgadoV. FerenceB.A. GrahamI.M. HallidayA. LandmesserU. MihaylovaB. PedersenT.R. RiccardiG. RichterD.J. SabatineM.S. TaskinenM.R. TokgozogluL. WiklundO. MuellerC. DrexelH. AboyansV. CorsiniA. DoehnerW. FarnierM. GiganteB. KayikciogluM. KrstacicG. LambrinouE. LewisB.S. MasipJ. MoulinP. PetersenS. PetronioA.S. PiepoliM.F. PintóX. RäberL. RayK.K. ReinerŽ. RiesenW.F. RoffiM. SchmidJ-P. ShlyakhtoE. SimpsonI.A. StroesE. SudanoI. TselepisA.D. ViigimaaM. VindisC. VonbankA. VrablikM. VrsalovicM. ZamoranoJ.L. ColletJ-P. KoskinasK.C. CasulaM. BadimonL. John ChapmanM. De BackerG.G. DelgadoV. FerenceB.A. GrahamI.M. HallidayA. LandmesserU. MihaylovaB. PedersenT.R. RiccardiG. RichterD.J. SabatineM.S. TaskinenM-R. TokgozogluL. WiklundO. WindeckerS. AboyansV. BaigentC. ColletJ-P. DeanV. DelgadoV. FitzsimonsD. GaleC.P. GrobbeeD. HalvorsenS. HindricksG. IungB. JüniP. KatusH.A. LandmesserU. LeclercqC. LettinoM. LewisB.S. MerkelyB. MuellerC. PetersenS. PetronioA.S. RichterD.J. RoffiM. ShlyakhtoE. SimpsonI.A. Sousa-UvaM. TouyzR.M. NiboucheD. ZelveianP.H. SiostrzonekP. NajafovR. van de BorneP. PojskicB. PostadzhiyanA. KyprisL. ŠpinarJ. LarsenM.L. EldinH.S. ViigimaaM. StrandbergT.E. FerrièresJ. AgladzeR. LaufsU. RallidisL. BajnokL. GudjónssonT. MaherV. HenkinY. GuliziaM.M. MussagaliyevaA. BajraktariG. KerimkulovaA. LatkovskisG. HamouiO. SlapikasR. VisserL. DingliP. IvanovV. BoskovicA. NazziM. VisserenF. MitevskaI. RetterstølK. JankowskiP. Fontes-CarvalhoR. GaitaD. EzhovM. FoscoliM. GigaV. PellaD. FrasZ. de IslaL.P. HagströmE. LehmannR. AbidL. OzdoganO. MitchenkoO. PatelR.S. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.Eur. Heart J.202041111118810.1093/eurheartj/ehz45531504418
     [Google Scholar]
  128. JacobsonT.A. ItoM.K. MakiK.C. OrringerC.E. BaysH.E. JonesP.H. McKenneyJ.M. GrundyS.M. GillE.A. WildR.A. WilsonD.P. BrownW.V. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary.J. Clin. Lipidol.20148547348810.1016/j.jacl.2014.07.00725234560
     [Google Scholar]
  129. HandelsmanY. JellingerP.S. GuerinC.K. BloomgardenZ.T. BrintonE.A. BudoffM.J. DavidsonM.H. EinhornD. FazioS. FonsecaV.A. GarberA.J. GrunbergerG. KraussR.M. MechanickJ.I. RosenblitP.D. SmithD.A. WyneK.L. Consensus statement by the America Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention cardiovascular disease algorithm – 2020 – Executive summary.Endocr. Pract.202026101196122410.4158/CS‑2020‑049033471721
     [Google Scholar]
  130. BerglundL. BrunzellJ.D. GoldbergA.C. GoldbergI.J. SacksF. MuradM.H. StalenhoefA.F.H. Evaluation and treatment of hypertriglyceridemia: An Endocrine Society clinical practice guideline.J. Clin. Endocrinol. Metab.20129792969298910.1210/jc.2011‑321322962670
     [Google Scholar]
  131. US Food and Drug Administration (FDA)FDA drug safety communication: Important safety label changes to cholesterol-lowering statin drugs.Available from: http://www.fda.gov/drugs/drugsafety/ucm293101.htm
  132. PonzianiM.C. KaramouzisI. MeleC. ChasseurL. ZavattaroM. CaputoM. SamàM.T. BustiA. PaganoL. CastelloL. MarzulloP. AimarettiG. ProdamF. Baseline glucose homeostasis predicts the new onset of diabetes during statin therapy: A retrospective study in real life.Hormones201716439640429518760
     [Google Scholar]
  133. GuberK. PemmasaniG. MalikA. AronowW.S. YandrapalliS. FrishmanW.H. Statins and higher diabetes mellitus risk: Incidence, proposed mechanisms, and clinical implications.Cardiol. Rev.202129631432210.1097/CRD.000000000000034832947479
     [Google Scholar]
  134. RajpathakS.N. KumbhaniD.J. CrandallJ. BarzilaiN. AldermanM. RidkerP.M. Statin therapy and risk of developing type 2 diabetes: A meta-analysis.Diabetes Care200932101924192910.2337/dc09‑073819794004
     [Google Scholar]
  135. SattarN. PreissD. MurrayH.M. WelshP. BuckleyB.M. de CraenA.J.M. SeshasaiS.R.K. McMurrayJ.J. FreemanD.J. JukemaJ.W. MacfarlaneP.W. PackardC.J. StottD.J. WestendorpR.G. ShepherdJ. DavisB.R. PresselS.L. MarchioliR. MarfisiR.M. MaggioniA.P. TavazziL. TognoniG. KjekshusJ. PedersenT.R. CookT.J. GottoA.M. ClearfieldM.B. DownsJ.R. NakamuraH. OhashiY. MizunoK. RayK.K. FordI. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials.Lancet2010375971673574210.1016/S0140‑6736(09)61965‑620167359
     [Google Scholar]
  136. PreissD. SeshasaiS.R. WelshP. MurphyS.A. HoJ.E. WatersD.D. DeMiccoD.A. BarterP. CannonC.P. SabatineM.S. BraunwaldE. KasteleinJ.J. de LemosJ.A. BlazingM.A. PedersenT.R. TikkanenM.J. SattarN. RayK.K. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis.JAMA2011305242556256410.1001/jama.2011.86021693744
     [Google Scholar]
  137. SeoW.W. SeoS.I. KimY. YooJ.J. ShinW.G. KimJ. YouS.C. ParkR.W. ParkY.M. KimK.J. RheeS.Y. ParkM. JinE.S. KimS.E. Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: A distributed network analysis of 10 real-world databases.Cardiovasc. Diabetol.20222118210.1186/s12933‑022‑01524‑635606846
     [Google Scholar]
  138. BraultM. RayJ. GomezY.H. MantzorosC.S. DaskalopoulouS.S. Statin treatment and new-onset diabetes: A review of proposed mechanisms.Metabolism201463673574510.1016/j.metabol.2014.02.01424641882
     [Google Scholar]
  139. ZhaoS.P. ZhaoW. Different effects of statins on induction of diabetes mellitus: An experimental study.Drug Des. Devel. Ther.201596211622310.2147/DDDT.S8797926648697
     [Google Scholar]
  140. NomuraS. ShouzuA. OmotoS. InamiN. TanakaA. NanbaM. ShoudaY. TakahashiN. KimuraY. IwasakaT. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus.Thromb. Res.20081221394510.1016/j.thromres.2007.08.01317920663
     [Google Scholar]
  141. ChruścielP. SahebkarA. WieliczkoR.M. SerbanM.C. UrsoniuS. MikhailidisD.P. JonesS.R. MosteoruS. BlahaM.J. MartinS.S. RyszJ. TothP.P. LipG.Y.H. PencinaM.J. RayK.K. BanachM. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms.Atherosclerosis201625319420810.1016/j.atherosclerosis.2016.07.89727498397
     [Google Scholar]
  142. RinellaM.E. LazarusJ.V. RatziuV. FrancqueS.M. SanyalA.J. KanwalF. RomeroD. AbdelmalekM.F. AnsteeQ.M. ArabJ.P. ArreseM. BatallerR. BeuersU. BoursierJ. BugianesiE. ByrneC.D. Castro NarroG.E. ChowdhuryA. Cortez-PintoH. CryerD.R. CusiK. El-KassasM. KleinS. EskridgeW. FanJ. GawriehS. GuyC.D. HarrisonS.A. KimS.U. KootB.G. KorenjakM. KowdleyK.V. LacailleF. LoombaR. Mitchell-ThainR. MorganT.R. PowellE.E. RodenM. Romero-GómezM. SilvaM. SinghS.P. SookoianS.C. SpearmanC.W. TiniakosD. ValentiL. VosM.B. WongV.W.S. XanthakosS. YilmazY. YounossiZ. HobbsA. RivasV.M. NewsomeP.N. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.Hepatology20237861966198610.1097/HEP.000000000000052037363821
     [Google Scholar]
  143. EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.J. Hepatol.20166461388140210.1016/j.jhep.2015.11.004
     [Google Scholar]
  144. PowellE.E. WongV.W.S. RinellaM. Non-alcoholic fatty liver disease.Lancet2021397102902212222410.1016/S0140‑6736(20)32511‑333894145
     [Google Scholar]
  145. ChalasaniN. YounossiZ. LavineJ.E. CharltonM. CusiK. RinellaM. HarrisonS.A. BruntE.M. SanyalA.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.Hepatology201867132835710.1002/hep.2936728714183
     [Google Scholar]
  146. WongC.R. LimJ.K. The association between nonalcoholic fatty liver disease and cardiovascular disease outcomes.Clin. Liver Dis.2018122394410.1002/cld.72130988909
     [Google Scholar]
  147. KanwalF. ShubrookJ.H. YounossiZ. NatarajanY. BugianesiE. RinellaM.E. HarrisonS.A. MantzorosC. PfotenhauerK. KleinS. EckelR.H. KrugerD. El-SeragH. CusiK. Preparing for the NASH epidemic: A call to action.Diabetes Care20214492162217210.2337/dci21‑002034312182
     [Google Scholar]
  148. TaharbouchtS. GuermazR. BrouriM. ChibaneA. Pre-diabetes and NAFLD; A study of an Algerian population sample.Endocr. Metabol. Sci.202013-410006010.1016/j.endmts.2020.100060
     [Google Scholar]
  149. TargherG. CoreyK.E. ByrneC.D. RodenM. The complex link between NAFLD and type 2 diabetes mellitus — Mechanisms and treatments.Nat. Rev. Gastroenterol. Hepatol.202118959961210.1038/s41575‑021‑00448‑y33972770
     [Google Scholar]
  150. ParkJ. KwonH.J. SohnW. ChoJ.Y. ParkS.J. ChangY. RyuS. KimB.I. ChoY.K. Risk of liver fibrosis in patients with prediabetes and diabetes mellitus.PLoS One2022176e026907010.1371/journal.pone.026907035653399
     [Google Scholar]
  151. SoutoK.P. MeinhardtN.G. RamosM.J. Ulbrich-KulkzynskiJ.M. SteinA.T. DaminD.C. Nonalcoholic fatty liver disease in patients with different baseline glucose status undergoing bariatric surgery: Analysis of intraoperative liver biopsies and literature review.Surg. Obes. Relat. Dis.2018141667310.1016/j.soard.2017.09.52729104004
     [Google Scholar]
  152. WongV.W.S. AdamsL.A. de LédinghenV. WongG.L.H. SookoianS. Noninvasive biomarkers in NAFLD and NASH — current progress and future promise.Nat. Rev. Gastroenterol. Hepatol.201815846147810.1038/s41575‑018‑0014‑929844588
     [Google Scholar]
  153. CaussyC. ReederS.B. SirlinC.B. LoombaR. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials.Hepatology201868276377210.1002/hep.2979729356032
     [Google Scholar]
  154. BerzigottiA. TsochatzisE. BoursierJ. CasteraL. CazzagonN. RustF.M. PettaS. ThieleM. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update.J. Hepatol.202175365968910.1016/j.jhep.2021.05.02534166721
     [Google Scholar]
  155. WongV.W.S. WongG.L.H. TsangS.W.C. HuiA.Y. ChanA.W.H. ChoiP.C.L. ChimA.M.L. ChuS. ChanF.K.L. SungJ.J.Y. ChanH.L.Y. Metabolic and histological features of non‐alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.Aliment. Pharmacol. Ther.200929438739610.1111/j.1365‑2036.2008.03896.x19035982
     [Google Scholar]
  156. RatziuV. CharlotteF. HeurtierA. GombertS. GiralP. BruckertE. GrimaldiA. CapronF. PoynardT. Sampling variability of liver biopsy in nonalcoholic fatty liver disease.Gastroenterology200512871898190610.1053/j.gastro.2005.03.08415940625
     [Google Scholar]
  157. BedossaP. ConsortiumF.P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease.Hepatology201460256557510.1002/hep.2717324753132
     [Google Scholar]
  158. DavisonB.A. HarrisonS.A. CotterG. AlkhouriN. SanyalA. EdwardsC. ColcaJ.R. IwashitaJ. KochG.G. DittrichH.C. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.J. Hepatol.20207361322133210.1016/j.jhep.2020.06.02532610115
     [Google Scholar]
  159. EASL-ALEH clinical practice guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.J. Hepatol.201563123726410.1016/j.jhep.2015.04.00625911335
     [Google Scholar]
  160. MahadyS.E. MacaskillP. CraigJ.C. WongG.L.H. ChuW.C.W. ChanH.L.Y. GeorgeJ. WongV.W.S. Diagnostic accuracy of noninvasive fibrosis scores in a population of individuals with a low prevalence of fibrosis.Clin. Gastroenterol. Hepatol.201715914531460.e110.1016/j.cgh.2017.02.03128286195
     [Google Scholar]
  161. HagströmH. TalbäckM. AndreassonA. WalldiusG. HammarN. Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease.Gastroenterology2020158120021410.1053/j.gastro.2019.09.00831563624
     [Google Scholar]
  162. CusiK. OrsakB. BrilF. LomonacoR. HechtJ. LopezO.C. TioF. HardiesJ. DarlandC. MusiN. WebbA. SanchezP.P. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial.Ann. Intern. Med.2016165530531510.7326/M15‑177427322798
     [Google Scholar]
  163. LianJ. FuJ. Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: A meta-analysis.Front. Endocrinol.20211261540910.3389/fendo.2021.61540933995271
     [Google Scholar]
  164. LianJ. FuJ. Efficacy of various hypoglycemic agents in the treatment of patients with nonalcoholic liver disease with or without diabetes: A network meta-analysis.Front. Endocrinol.20211264901810.3389/fendo.2021.64901833841337
     [Google Scholar]
  165. TaheriH. MalekM. BeigiI.F. ZamaniF. SohrabiM. babaeiR.M. KhamsehM.E. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: A randomized, double-blind, placebo-controlled trial.Adv. Ther.202037114697470810.1007/s12325‑020‑01498‑532975679
     [Google Scholar]
  166. ChengS. GeJ. ZhaoC. LeS. YangY. KeD. WuN. TanX. ZhangX. DuX. SunJ. WangR. ShiY. BorraR.J.H. ParkkolaR. WiklundP. LuD. Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized controlled trial.Sci. Rep.2017711595210.1038/s41598‑017‑16159‑x29162875
     [Google Scholar]
  167. ShekaA.C. AdeyiO. ThompsonJ. HameedB. CrawfordP.A. IkramuddinS. Nonalcoholic steatohepatitis.JAMA2020323121175118310.1001/jama.2020.229832207804
     [Google Scholar]
  168. EguchiY. WongG. LeeE.I.H. AkhtarO. LopesR. SumidaY. Epidemiology of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: A focused literature review.JGH Open20204580881710.1002/jgh3.1234933102749
     [Google Scholar]
  169. CusiK. IsaacsS. BarbD. BasuR. CaprioS. GarveyW.T. KashyapS. MechanickJ.I. MouzakiM. NadolskyK. RinellaM.E. Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the american association for the study of liver diseases (AASLD).Endocr. Pract.202228552856210.1016/j.eprac.2022.03.01035569886
     [Google Scholar]
  170. WongV.W.S. ChanW.K. ChitturiS. ChawlaY. DanY.Y. DusejaA. FanJ. GohK.L. HamaguchiM. HashimotoE. KimS.U. LesmanaL.A. LinY.C. LiuC.J. NiY.H. SollanoJ. WongS.K.H. WongG.L.H. ChanH.L.Y. FarrellG. Asia-pacific working party on non-alcoholic fatty liver disease guidelines 2017—part 1: Definition, risk factors and assessment.J. Gastroenterol. Hepatol.2018331708510.1111/jgh.1385728670712
     [Google Scholar]
  171. ElSayedN.A. AleppoG. ArodaV.R. BannuruR.R. BrownF.M. BruemmerD. CollinsB.S. CusiK. HilliardM.E. IsaacsD. JohnsonE.L. KahanS. KhuntiK. LeonJ. LyonsS.K. PerryM.L. PrahaladP. PratleyR.E. SeleyJ.J. StantonR.C. YounossiZ. GabbayR.A. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of care in diabetes—2023.Diabetes Care202346S1s49, s67.210.2337/dc23‑S00436507651
     [Google Scholar]
/content/journals/emiddt/10.2174/0118715303282327240507184902
Loading
Obesity in Prediabetic Patients: Management of Metabolic Complications and Strategies for Prevention of Overt Diabetes
Endocr Metab Immune Disord Drug Targets 25, 8 (2025); https://doi.org/10.2174/0118715303282327240507184902
/content/journals/emiddt/10.2174/0118715303282327240507184902
/content/journals/emiddt/10.2174/0118715303282327240507184902
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): diabetes prevention; fatty liver disease; lifestyle; nutrition; Obesity; obesity comorbidities; pharmacological therapy; prediabetes

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test